Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy by Melacini, Paola et al.
.....................................................................................................................................................................................
.....................................................................................................................................................................................
CLINICAL RESEARCH
Heart failure/cardiomyopathy
Clinicopathological proﬁles of progressive heart
failure in hypertrophic cardiomyopathy
PaolaMelacini1*, CristinaBasso2, AnnalisaAngelini2,C h i a r aC a l o r e 1, FabianaBobbo1,
Barbara Tokajuk1, Nicoletta Bellini1, Gessica Smaniotto3, Mauro Zucchetto4,
Sabino Iliceto1, Gaetano Thiene2,a n dB a r r yJ .M a r o n 5
1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Via Giustiniani 2, 35100 Padova, Italy;
2Department of Medico-Diagnostic Sciences and
Special Therapies, University of Padua Medical School, Padova, Italy;
3Department of Biology, University of Padua Medical School, Padova, Italy;
4Padua Research, Padova, Italy; and
5Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA
Received 20 October 2009; revised 15 March 2010; accepted 9 April 2010; online publish-ahead-of-print 31 May 2010
Aims Hypertrophic cardiomyopathy (HCM) is an important cause of heart failure-related disability over a wide range of
ages. Proﬁles of severe progressive heart failure symptoms and death, or heart transplantation deserve more com-
plete deﬁnition within large patient cohorts.
Methods
and results
Clinical and morphological features of heart failure were assessed in 293 consecutive HCM patients over a median
follow-up of 6 (inter-quartile range 2–11) years. Gross and histopathological features were analysed in 12 patients
for whom the heart was available for inspection. Of the 293 patients, 50 (17%) developed severe progressive heart
failure, including 18 who died or were transplanted. Three proﬁles of heart failure were identiﬁed predominantly associ-
ated with: (i) end-stage systolic dysfunction (ejection fraction ,50%) (15; 30%); (ii) left ventricular (LV) outﬂow obstruc-
tion at rest (11; 22%); and (iii) non-obstructive with preserved systolic function (24; 48%). Overall, atrial ﬁbrillation (AF)
contributed to heart failure in 32 patients (64%) among the three proﬁles. Compared with other patients, those non-
obstructive with preserved systolic function had earlier onset of heart failure symptoms mainly due to diastolic dysfunc-
tion, and the most accelerated progression to advanced heart failure and adverse outcome (P ¼ 0.04). Thrombi were
identiﬁed in the left atrial appendage of ﬁve gross heart specimens all belonging to patients with AF, including three of
which were unrecognized clinically and had previously embolized. Extensive myocardial scarring with LV remodelling
was evident in all end-stage patients; no or only focal scars were present in other patients.
Conclusion Proﬁles of advanced heart failure in HCM are due to diverse pathophysiological mechanisms, including LV outﬂow
obstruction and diastolic or global systolic ventricular dysfunction. Atrial ﬁbrillation proved to be the most
common disease variable associated with progressive heart failure. Recognition of the heterogeneous pathophysiol-
ogy of heart failure in HCM is relevant, given the targeted management strategies necessary in this disease.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Hypertrophic cardiomyopathy (HCM) is the most common
genetic cardiac disease
1,2 with a prevalence of 1:500 in the
general population.
2 The clinical presentation and natural history
is particularly heterogeneous, ranging from benign asymptomatic
forms to more malignant expressions that may result in premature
death through several pathways.
2–4
Although the risk for sudden cardiac death in young patients
has been a highly visible complication, it should be underscored
that HCM is also an important cause of heart failure-related
disability and death. Moreover, it is now evident that progressive
heart failure in HCM does not occur in a single unique
clinical setting, but under a variety of circumstances due to
*Corresponding author. Tel: +39 049 8211776, Fax: +39 049 8761764, Email: paola.melacini@unipd.it
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
European Heart Journal (2010) 31, 2111–2123
doi:10.1093/eurheartj/ehq136diverse pathophysiological mechanisms.
1,2 We have longitudinally
assessed a large consecutive single-institution cohort of HCM
patients, to derive insights into the proﬁles and pathophysiology
of heart failure in this complex disease.
Methods
Patient selection
From January 1980 to November 2001, 293 consecutive patients with
HCM were evaluated in Padua University HCM Center and were
assessed for the occurrence and clinicopathological proﬁle of
progressive, severe heart failure. Median follow-up was 6 years
(inter-quartile range 2–11 years). Fifty-one patients with chest pain
underwent coronary arteriography and 12 had obstructive coronary
artery disease (CAD) (i.e. diameter stenosis .75% of ≥1 major
epicardial coronary artery).
Echocardiography
Echocardiographic studies were performed with IREX System III,
Hewlett–Packard 77020, and SONOS 1000, 2500, 5500 instruments.
Maximal left ventricular (LV) wall thickness was the greatest dimension
within the chamber. Left ventricular cavity and left atrial dimensions
were obtained from M-mode echocardiograms, derived from two-
dimensional images.
5 Outﬂow obstruction at rest, due to mitral valve
systolic anterior motion, was identiﬁed by peak instantaneous LV
outﬂow gradient ≥30 mmHg.
6 Left ventricular ejection fraction was
calculated from two-dimensional images with modiﬁed Simpson’s
formula or area–length method.
5
Parameters of LV ﬁlling were obtained with pulsed Doppler echo-
cardiography:
7 peak ﬂow velocity in early diastole (E) and during
atrial contraction (A), and E/A ratio; deceleration time (DT) of early
diastolic ﬂow velocity (descent of E/F slope).
7
Deﬁnitions
Hypertrophic cardiomyopathy was diagnosed by a hypertrophied non-
dilated LV, with absolute wall thickness ≥13 mm (or the equivalent
corrected for body size in children), in the absence of another
cardiac or systemic disease capable of producing the magnitude of
hypertrophy evident, at some point in the clinical course.
1,2
Heart failure death was deﬁned as progressive cardiac decompensa-
tion over ≥1 year before death or transplant, which frequently
required hospitalization, particularly if complicated by pulmonary
oedema. Severe progressive heart failure is deﬁned as symptomatic evol-
ution to New York Heart Association (NYHA) functional class III/IV,
characterized by exertional dyspnoea (with or without chest pain),
refractory to maximal medical management. Diastolic dysfunction
causing symptoms of heart failure requires two conditions to be satis-
ﬁed: (i) normal LV systolic function (ejection fraction .50%); and (ii)
evidence of abnormal LV relaxation and distensibility as deﬁned by
pulsed Doppler echocardiography.
8,9 Abnormal LV relaxation (mild or
grade 1 diastolic dysfunction) was deﬁned as a decrease in early diastolic
ﬂow velocity (reduced E-wave amplitude) associated with increase in
atrial contraction (greater A-wave amplitude) with E/A ,1. Restrictive
LV ﬁlling pattern was considered present in the setting of sinus
rhythm and shortened DT , 150 ms and E/A . 2.
8
Genetics
Mutation screening of exon 2–40 of MYH7 gene, exon 1–35 of
MYBPC3 gene, and exon 1–8 and exon 8–16 of TNNI3 and TNNT2
genes, respectively, was performed in 18 of 50 patients with
progressive heart failure. The method consisted of PCR ampliﬁcation
of each DNA segment, denaturing high-performance liquid chromato-
graphy and DNA sequencing of segments showing extra peaks. Novel
mutations were surveyed for polymorphism in a large cohort of
healthy controls (n ¼ 400).
Pathology
Gross examination addressed heart weight, LV wall thickness (i.e.
exclusive papillary muscles and trabeculae), chamber dilatation (0 to
3+), coronary arterial anatomy, and scarring. Full-thickness tissue
blocks were obtained from ventricular septum and LV free wall.
Tissue specimens were embedded in parafﬁn, sectioned at 6 mm and
stained with haematoxylin–eosin and azan-Heidenhein trichrome.
Blocks were examined microscopically to assess myocyte disarray,
interstitial and replacement ﬁbrosis, and intramural small vessel
disease.
10–13 Fibrosis was deﬁned as interstitial when myocytes were
encircled by collagen matrix and replacement-type when myocytes
were substituted by connective tissue. Disarray and ﬁbrosis were
graded 0 to 3+.
Statistical analysis
Data are expressed as mean+SD for continuous variables. Differ-
ences between means were tested by unpaired Student’s t-test. Categ-
orical frequencies were compared by x
2 or Fisher’s exact test, where
appropriate. Probability values reported are two-sided, and values
,0.05 were considered statistically signiﬁcant. SAS Statistical System
9.1 (SAS Institute Inc., Cary, NC, USA) and SPSS Statistics 17.0
(SPSS Inc., Chicago, IL, USA) were used for analysis.
Results
Advanced heart failure
Progressive heart failure leading to NYHA functional classes III and
IV occurred in 50 of 293 study patients (17%; Table 1). Among the
remaining 243 patients who developed mild or no heart failure,
160 (66%) had NYHA I and 83 (34%) NYHA II. Incidence of
advanced heart failure and death was 24/1000 HCM patient-years
(95% conﬁdence interval: 18–32). Of the 50 patients, 10 died of
heart failure and 8 underwent heart transplantation. Patients with
advanced heart failure were 41+20 years old at HCM diagnosis
and 48+19 years at HCM-related heart failure symptom onset
(interval 7+9 years). Compared with other study patients,
those with progressive heart failure were more commonly
women and, more frequently, had atrial ﬁbrillation (AF) and
moderate-to-severe mitral regurgitation (Table 1). No statistically
signiﬁcant difference in CAD prevalence was found between
patients in NYHA III–IV and those in NYHA I–II heart failure
classes. Among the 51 patients who underwent coronary arterio-
graphy, 12 (24%) were ≤39 years old, 20 (39%) were 40–59 years,
and the remaining 19 (37%) ≥60 years; CAD was detectable only
in the two older age groups, i.e. in 4 patients 40–59 years of age
and in 8 patients aged .60 years.
Proﬁles of heart failure
Three diverse proﬁles of severe heart failure were deﬁned, based
on the predominant pathophysiological disease component: (i)
end-stage systolic dysfunction (n ¼ 15; 30%); (ii) LV outﬂow
P. Melacini et al. 2112obstruction (n ¼ 11; 22%); and (iii) non-obstructive with preserved
systolic function (n ¼ 24; 48%) (Tables 2 and 3; Figures 1–5).
End-stage systolic dysfunction
In 15 patients (30%), heart failure symptoms progressed due to the
end-stage phase with systolic dysfunction (ejection fraction ,50%;
mean 40+6%)
14 (Tables 2 and 3). Age at diagnosis was 46+20
years with a 11+12-year interval between diagnosis and heart
failure symptom onset. Left ventricular end-diastolic dimension at
most recent follow-up was greatest in this subgroup (56+10 vs.
44+7 for others, P ¼ 0.001).
Of the 15 end-stage patients, 11 had AF, either at study entry
(n ¼ 4) or during follow-up with progression of heart failure
(n ¼ 7). Among the 15 patients, 3 died of heart failure (one with
a prior renal embolic event (Patient #8), 3 were transplanted,
and 1 is awaiting a donor heart.
Left ventricular outﬂow obstruction
Progressive heart failure was the consequence of outﬂow obstruc-
tion in 11 patients (22%).
15 Six of these 11 patients had the com-
bination of outﬂow obstruction and paroxysmal or permanent AF
(Tables 3). Initial peak resting systolic subaortic gradients were
58+20 mmHg (range 40–110). Advanced heart failure symptoms
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Table 1 Baseline characteristics in hypertrophic cardiomyopathy patients with or without progressive heart failure
Variable Heart failure P-value
NYHA III–IV NYHA I–II
Patients 50 243
Female gender 27 (54%) 76 (31%) 0.008
Age at diagnosis (years) 41+20 42+18 0.8
Family history of HCM 20 (40%) 94 (39%) 0.9
Atrial ﬁbrillation, at entry and/or during follow-up 32 (64%) 49 (20%) ,0.0001
Atrial ﬁbrillation at entry 10 (20%) 14 (6%) 0.003
Paroxysmal 1 (2%) 8 (3%)
Persistent 2 (4%) 1 (0.4%) }
,0.001
Permanent 7 (14%) 5 (2%)
Atrial ﬁbrillation during follow-up 32 (64%) 44 (18%) ,0.0001
Paroxysmal 8 (16%) 11 (4.5%)
Persistent 2 (4%) 17 (7%) }
,0.0001
Permanent 22 (44%) 16 (6.5%)
Implantable cardioverter-deﬁbrillator 3 (6%) 9 (4%) 0.45
LVOT gradient ≥30 mmHg at rest 12 (24%) 57 (23%) 1.0
LVOT gradient (mm Hg) 58+21 47+31 0.6
Surgical myectomy 3 (6%) 2 (1%) 0.04
Mitral regurgitation at entry
Present 35 (70%) 124 (51%)
Mild 22 (44%) 92 (38%) } 0.009
Moderate–severe 13 (26%) 32 (13%)
Left atrium diameter (mm) 48+11 41+9 ,0.0001
Left atrium volume index (mL/m
2)8 5 +32 61+23 0.0003
Max LV wall thickness (mm) 21+62 2 +6 0.3
LV end-diastolic diameter (mm) 46+84 3 +7 0.06
Ejection fraction (%) 60+13 63+9 0.14
NYHA class at entry (mean) 2.3+0.9 1.4+0.5 ,0.0001
Chest pain
Absent 36 (72%) 199 (82%)
Rest 7 (14%) 28 (11%) }
0.15
Effort 7 (14%) 16 (7%)
Non-sustained VT 15/39 (38%) 40/164 (24%) 0.1
Obstructive CAD, no. of patients/no. with angiography performed 3/16 (19%) 9/35 (26%) 0.8
CAD, coronary artery disease; HCM, hypertrophic cardiomyopathy; LV, left ventricle; LVOT, left ventricle outﬂow tract, NYHA, New York Heart Association; VT, ventricular
tachycardia.
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Table 2 Comparison of demographic, clinical, and functional data in three hypertrophic cardiomyopathy heart failure proﬁles
End-stage LVOTO Non-obstructive (preserved systolic
function)
P-values
All With AF NSR End-stage vs. LVOTO End-stage vs.
non-obstructive
(preserved systolic
function)
LVOTO vs.
non-obstructive
(preserved systolic
function)
No. of patients 15 11 24 15 9
Male 7 (47%) 5 (45%) 11 (46%) 8 (53%) 3 (33%) 0.9 0.9 0.9
Age at diagnosis (years) 46+20 50+14 35+20 36+15 34+27 0.5 0.1 0.02
Age at onset HF symptoms (years) 57+14 54+15 40+21 42+15 36+29 0.6 0.004 0.03
Age at death/transplant (years) 62+10 67 41+22 41+16 41+26 0.6 0.01 0.2
Interval: symptom onset to death/transplant (years) 5+67 6 +87 +83 +5 0.7 0.7 0.9
Death/transplant 6 (40%) 1 (9%) 11 (46%) 5 (33%) 6 (67%) 0.07 0.7 0.03
Left atrial dimension
At entry (mm) 49+94 4 +75 1 +13 53+12 46+15 0.1 0.6 0.1*
Most recent (mm) 55+75 3 +85 9 +23 63+24 50+17 0.5 0.6 0.4
Atrial ﬁbrillation
At entry 4 (27%) 1 (9%) 5 (21%) 5 (33%) 0 0.3 0.7 0.4
Most recent 11 (73%) 6 (54%) 15 (62%) 15 (100%) 0 0.3 0.6
† 0.5
‡
Ejection fraction
At entry (%) 51+16 69+96 2 +96 3 +96 1 +10 0.003 0.006 0.06
Most recent (%) 40+65 9 +76 0 +76 0 +76 2 +9 ,0.001 ,0.001 0.6
LV end-diastolic diameter
At entry (mm) 50+74 6 +64 3 +94 4 +94 0 +9 0.1 0.01 0.2
Most recent (mm) 56+10 43+54 4 +84 5 +74 1 +10 ,0.001 0.001 0.8
LVOT peak systolic gradient
At entry (mmHg) 5+17 58+21 3+73 +72 +5 ,0.001 0.6 ,0.001
Most recent (mmHg) 0+08 9 +59 0+20 1 +3 ,0.001 0.3 ,0.001
Diastolic dysfunction
At entry, n/n available 6/13 (46%) 1/7 (14%) 17/21 (81%) 8/12 (67%) 9/9 (100%) 0.1 0.04
§ 0.002
Most recent, n/n available 9/12 (75%) 1/3 (33%) 13/13 (100%) 6/6 (100%) 7/7 (100%) 0.2 0.05 0.002
CAD/coronary angiograms 2/8 0/2 1/6 1/4 0/2 0.4 0.7 0.5
Myectomy/MVR 0/0 2/2 0/2 0/2 0/0 0.09 n.a./0.2 0.03/0.4
AF, atrial ﬁbrillation; CAD, coronary artery disease; HF, heart failure; LV, left ventricle; LVOTO, left ventricular outﬂow tract obstruction; MVR, mitral valve replacement; n.a., not available; NSR, normal sinus rhythm.
*P ¼ 0.04 LVOTO vs. non-obstructive (preserved systolic function) with AF.
†P ¼ 0.03 end-stage vs. non-obstructive (preserved systolic function) with AF.
‡P ¼ 0.004 LVOTO vs. non-obstructive (preserved systolic function) with AF.
§P ¼ 0.007 end-stage vs. non-obstructive (preserved systolic function) with NSR.
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Table 3 Clinical data of hypertrophic cardiomyopathy patients with advanced heart failure
Patient
no.
Gender Gene mutation Age at
Dx,
years
Age at
symptom
onset, years
CAD LA
entry,
mm
LA
FU,
mm
AF
entry
AF
FU
LVOT peak
gradient
entry,
mmHg
LVOT peak
gradient FU,
mm Hg
EF
entry, %
EF
FU, %
Max-
LV,
mm
LVED
entry,
mm
LVED
FU,
mm
PW LV
ﬁlling
pattern
entry
PW LV
ﬁlling
pattern FU
MR
entry
MR
FU
NYHA
class
entry
NYHA
class FU
Surgery SE Outcome
(age)
End-stage
1 M 0 5 26 0 30 49 0 parox 0 0 62 38 25 45 60 E/A . 1E / A . 1 0 1 I III 0 0 Alive
2 F 0 11 40 — 51 50 0 0 15 0 58 40 32 43 62 E/A . 1E / A . 1 0 1 I III 0 0 List for TP
3 F 0 17 47 0 46 54 0 perm 0 0 61 46 20 48 57 E/A . 1 RES 0 1 II III 0 0 Alive, PM
4 M 0 38 38 — 65 68 0 perm 0 0 44 45 21 56 56 RES RES 1 0 II IV 0 0 TP (50)
5 M TNNT2 39 56 + 60 70 perm perm 0 0 26 30 13 58 62 RES RES 1 1 II III 0 0 TP (59)
EX 9
Arg94Leu
6 M — 39 59 — 48 56 0 perm 0 0 60 46 22 48 57 E/A . 1 RES 0 1 II III 0 0 Alive, ablation
7 M — 48 74 — 53 56 0 parox 0 0 74 46 25 51 47 E/A . 1E / A . 1 1 — I III 0 0 Alive, PM
8 F — 54 54 0 44 45 0 parox 0 0 47 46 25 45 31 RES RES 2 2 III III 0 + HF death (55)
9 F — 55 55 0 58 59 pers perm 0 0 25 47 19 60 61 — — 1 2 III III 0 0 Alive, PM, ICD
a
10 F 0 59 66 — 50 48 perm perm 0 0 32 36 18 40 38 — RES 1 1 II IV 0 0 HF death (68)
11 F MYBPC3 59 63 0 43 51 perm perm 0 0 34 31 16 55 58 RES RES 2 2 II III 0 0 TP (63)
EX 13
Gln366X
12 M — 64 65 0 42 60 0 0 0 0 40 32 18 35 68 E/A . 1 RES 2 3 I III 0 0 HF death (77)
13 F — 65 65 — 50 52 0 0 64 0 70 31 25 52 64 E/A , 1 — 2 0 III III 0 0 Alive
14 M — 65 80 + 52 58 0 perm 0 0 71 43 23 53 60 E/A . 1 — 1 0 I III CABG 0 Alive
15 F — 66 66 — 38 55 0 0 0 0 54 41 17 60 60 E/A . 1E / A . 1 0 0 IV III 0 0 Alive
LV outﬂow obstruction
16 M MYH7 16 16 — 45 51 0 0 80 50 83 58 35 50 40 E/A . 1E / A . 1 2 1 III III 0 0 Alive
EX 22
Met877Ile
17 M — 41 41 — 41 45 0 parox 40 190
b 75 66 21 41 40 E/A . 1E / A , 1 1 1 III III 0 0 Alive
18 M — 45 64 0 48 64 0 perm 55 40 75 50 25 52 55 E/A . 1 — 1 0 II III 0 0 Alive
19 F — 47 47 — 60 65 0 0 50 80 68 57 25 50 42 E/A . 1E / A . 1 1 2 IV III 0 0 Alive
20 M — 51 61 — 35 38 0 0 60 60 50 50 18 53 47 E/A . 1 — 0 1 III III 0 0 Alive, PM
21 F — 51 54 — 46 55 perm perm 50 60 62 66 28 38 40 — — 2 2 III III 0 0 Alive
22 M 0 52 58 0 38 58 0 perm 45 75 (0) 68 63 27 42 42 E/A . 1 — 2 2 III III (I) Myectomy +
MVR
0 Alive
23 F — 54 62 — 36 56 0 parox 40 40 (0) 77 67 29 40 41 E/A , 1 — 1 2 IV III (I) Myectomy +
MVR
0 Alive
24 F — 60 60 — 50 48 0 0 110 200 71 59 23 41 46 E/A . 1 — 2 2 III IV 0 0 Alive, PM
25 F — 60 60 — 40 54 0 perm 65 95 62 53 25 46 38 E/A . 1 — 1 1 II IV 0 0 HF death (67)
26 F — 72 72 — 45 — 0 0 45 — 68 — 19 51 — E/A . 1 — 2 — IV — 0 0 Lost
Non-obstructive with preserved systolic function + atrial ﬁbrillation
27 F — 14 34 — 57 60 0 parox 0 0 50 50 18 46 45 E/A . 1
c RES 3 3 II IV 0 + HF death (39)
28 M — 15 18 — 70 70 0 perm 0 0 72 65 14 40 40 RES — 1 0 III IV 0 0 TP (20)
29 M — 20 20 — 56 58 0 parox 0 0 70 64 18 57 38 RES — 0 3 (0) III III (II) MVR 0 Alive
30 M — 22 25 — 38 40 parox parox 0 0 46 56 25 60 60 E/A . 1 — 1 1 II III 0 + Alive, ICD
a
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Table 3 Continued
Patient
no.
Gender Gene mutation Age at
Dx,
years
Age at
symptom
onset, years
CAD LA
entry,
mm
LA
FU,
mm
AF
entry
AF
FU
LVOT peak
gradient
entry,
mmHg
LVOT peak
gradient FU,
mm Hg
EF
entry, %
EF
FU, %
Max-
LV,
mm
LVED
entry,
mm
LVED
FU,
mm
PW LV
ﬁlling
pattern
entry
PW LV
ﬁlling
pattern FU
MR
entry
MR
FU
NYHA
class
entry
NYHA
class FU
Surgery SE Outcome
(age)
31 F — 30 31 — 70 70 pers perm 0 0 63 60 20 25 36 RES RES 0 0 III IV 0 0 HF death (34)
32 M — 32 47 0 40 43 0 pers 0 0 63 70 23 45 46 E/A , 1E / A , 1 1 1 I III 0 0 Alive
33 F 0 32 32 + 47 48 0 perm 0 0 68 67 25 40 38 E/A , 1 — 0 1 II IV 0 + PM, HF death (53)
34 F — 35 43 0 38 61 0 perm 12 0 64 50 26 35 45 E/A , 1 — 1 2 II III 0 0 Alive, PM, list for TP
35 M 0 36 36 — 44 127 0 perm 20 — 75 55 22 50 48 E/A . 1 — 2 3 (0) II III (II) MVR 0 Alive,
36 M — 42 44 — 70 — perm perm 0 — 58 — 15 40 — — — 2 — III — 0 0 Lost
37 M 0 48 55 — 47 50 perm perm 0 0 57 65 32 40 42 — — 1 1 III III 0 0 Alive, PM
38 F MYH7, EX 36
Thr1760Met
48 58 — 60 56 0 pers 0 0 76 51 18 38 44 E/A . 1E / A , 1 1 1 II III 0 0 Alive
39 M MYH7, EX 27
Ile1207Met
49 58 — 62 90 perm perm 20 0 57 57 18 52 55 — RES 1 2 III IV 0 0 TP (60)
40 F — 57 57 — 40 44 0 perm 0 0 67 65 16 50 48 E/A . 1 RES 0 0 I III 0 0 Alive, PM
41 F — 63 65 0 55 — 0 perm 0 0 62 — 15 47 — RES — 2 — II III 0 0 Alive, ablation + PM
Non-obstructive with preserved systolic function + normal sinus rhythm
42 F MYBPC3 1 1 0 30 33 0 0 15 10 84 72 30 32 36 E/A , 1E / A . 1
c 1 0 IV IV 0 0 TP (12)
EX 12
Ala364Thr
43 M 0 4 4 — 60 61 0 0 0 0 52 53 15 30 29 RES RES 0 2 III III 0 0 TP (9)
44 F — 5 5 0 25 25 0 0 0 0 68 72 20 32 32 E/A . 1
c E/A . 1
c 0 0 III III 0 0 Alive
45 F TNNI3 28 28 — 53 — 0 0 0 0 59 58 17 38 — RES RES 0 0 III — 0 0 TP (28)
EX 8
Lys207Thr
46 F — 37 41 — 60 — 0 — 0 0 55 — 18 55 — RES — 0 0 IV — 0 0 HF death (41)
47 M — 45 56 — 39 46 0 0 0 0 60 68 24 49 48 E/A , 1 RES 1 1 II IV 0 0 ICD
d, HF death (56)
48 F 0 45 45 — 70 55 0 0 0 0 56 51 16 49 48 RES RES 1 1 II IV 0 0 PM, HF death (66)
49 F — 65 70 — 46 75 0 0 0 0 64 57 15 40 53 RES RES 0 0 I IV 0 0 Alive
50 M — 76 76 — 35 — 0 0 0 0 53 — 25 37 — E/A . 1
c — 1 — II IV 0 0 Non-HCM-related
death (76)
AF, atrial ﬁbrillation classiﬁed as paroxysmal (parox), persistent (pers) or permanent (perm); CABG, coronary artery bypass graft; CAD, coronary artery disease; Dx, diagnosis; EF, ejection fraction; FU, follow-up; HCM, hypertrophic
cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LA, left atrium; LVED, left ventricle end-diastolic diameter; LV, left ventricle; LVOT, left ventricular outﬂow tract; MR, mitral regurgitation; MVR, mitral valve
replacement; NYHA, New York Heart Association; PM, pacemaker; RES, restrictive (deﬁned in setting of early LV diastolic ﬁlling deceleration time ,150 ms and E/A ratio .2 at sinus rhythm); SE, systemic embolism; TP, transplant; —, data
non available; +, present; 0, absent; () data after surgery.
aImplanted for secondary prevention.
bZero gradient at rest, and 190 mmHg with exercise.
cPseudo-normal LV ﬁlling pattern [deﬁned in the setting of E/A ratio ¼ 0.9–1.5, early LV diastolic ﬁlling deceleration time ¼ 160–240 ms, Valsalva positive (¼ E/A ratio decrease by ≥0.5 and increase in Avelocity during Valsalva manoeuvre)].
8
dImplanted for primary prevention.
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6(NYHA classes III–IV) due to outﬂow obstruction were present at
entry in nine patients and developed during follow-up in two. Two
patients underwent mitral valve replacement (associated with
myectomy), resulting in reduction of outﬂow gradient, three
refused surgery including one lost to follow-up and one who
died of heart failure. Patients with outﬂow obstruction were
older at diagnosis (50+14 years) and had greater LV wall thick-
ness (25+5 mm) than other heart failure patients (39+20
years; P ¼ 0.06 and 21+5 mm; P ¼ 0.02).
Non-obstructive with preserved systolic function
The remaining 24 patients (48%) showed advanced heart failure
without systolic dysfunction (ejection fraction ≥50%) or LV
outﬂow obstruction. Diastolic dysfunction was commonly
present in 17 patients at study entry and in all 13 for whom
these data were available at last follow-up (Tables 2 and 3).
Moreover, a restrictive ﬁlling pattern was present in 13 patients
at entry and/or at last follow-up (Table 3).
Of the 24 patients in this subgroup, AF adversely impacted clini-
cal course in 15 (62%), either recurrent and paroxysmal (n ¼ 3) or
persistent and permanent (n ¼ 12) (Tables 2 and 3). In AF patients,
marked left atrial enlargement was present at study entry (53+
12 mm) and increased 11+23 mm over follow-up. Initial left
atrial dimension in this subgroup was greater than in patients
with LV outﬂow obstruction (44+7 mm; P ¼ 0.04), but similar
to that in end-stage patients.
Six patients died of heart failure, ﬁve were transplanted (one
awaiting donor heart), and three experienced embolic stroke
(#27, #30, and #33; Table 3). Of note, three patients were diag-
nosed at particularly young ages of ≤5 years, subsequently devel-
oped progressive heart failure due to diastolic dysfunction at sinus
rhythm and two underwent heart transplantation at ages 9 and
Figure 1 Time lines shown for the three hypertrophic cardiomyopathy patient subgroups and disease proﬁles associated with severe, pro-
gressive heart failure. Patient ages at intervals describe clinical evolution. FU, follow-up.
Proﬁles of heart failure in HCM 211712 years (#43 and #42; Table 3). Compared with the other two
heart failure proﬁles combined, patients who were non-obstructive
with preserved systolic function became symptomatic earlier in life
(40+21 vs. 56+11 years; P ¼ 0.002) and showed the most
accelerated progression to advanced heart failure (NYHA classes
III–IV at 44+23 vs. 57+15 years; P ¼ 0.01) and adverse
outcome (41+21 vs. 63+9 years at death or transplant; P ¼
0.02). Progression of heart failure was most delayed in patients
with LV outﬂow obstruction and end-stage (Figure 1).
Pathological features
Heart specimens from 12 patients were available for gross visual
and histopathological examination, including 4 from autopsy and
8 from transplantation (Table 4 and Figures 2–5). Heart weights
were similar among heart failure subgroups; P ¼ 0.2.
All end-stage patients showed LV chamber dilatation with
diffuse, often transmural, ﬁbrous replacement in ventricular
septum and LV free wall (Figure 2). In contrast, only isolated or
patchy focal areas of scarring in the absence of LV chamber remo-
delling were present in four of the eight hearts with the non-
obstructive and preserved systolic function clinical proﬁle
(Figure 3). Two gross morphological patterns were evident with
diastolic dysfunction (in the absence of signiﬁcant scarring): (i)
small ventricles and mild hypertrophy (associated with restrictive
physiology) (Figure 4); and (ii) massive hypertrophy and particularly
small ventricular cavities (Figure 5).
Atria were available for inspection from ﬁve hearts, i.e. four non-
obstructive with preserved systolic function and one end-stage (all
with AF), including four at autopsy and one explanted. Each had left
atrial enlargement, 45–90 mm by echocardiography, and contained
a small (2–4 mm diameter) mobile and weakly attached thrombus
within the intertrabecular spaces of the pectinate muscles of the
left atrial appendage (Figure 3E). In each of these patients, the
thrombus was unsuspected clinically, but had apparently embolized
leading to stroke or renal infarct in three (#8, #27, and#33), all
without anticoagulation. The remaining two patients with atrial
thrombi (#31 and #39) were treated with prophylactic warfarin
or aspirin and experienced no embolic events.
Histopathological features of HCM, such as myocyte disarray
10
and increased interstitial ﬁbrosis,
13 were present in each of the
12 hearts; and abnormal intramural arterioles with thickened
walls and narrowed lumen were evident in 8.
Figure 2 End-stage systolic dysfunction. A 59-year-old transplanted male patient with a troponin T mutation [#5 (Table 3); #3 (Table 4)].
(A) Four-chamber view at end-diastole showing dilatation of both atria [transverse left atrial (LV) dimension ¼ 70 mm], left ventricular (LV)
enlargement (i.e. 62 mm), and mild hypertrophy [septal (VS) thickness; 13 mm]; ejection fraction was 30%. (B) Heart removed at transplan-
tation. Note thinning of basal and mid-ventricular septum (12 mm) compared with distal LV. (C) High power of boxed area in (B). Greyish
areas (arrows) are indicative of septal scarring. (D) Area of septum shown in (C). Extensive replacement ﬁbrosis is associated with abnormal
intramural arterioles. Trichrome stain ×60. RA, right atrium; RV, right ventricle.
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Disease-causing sarcomeric protein mutations were identiﬁed in 7
of 18 unrelated patients. b-Myosin heavy chain mutations were
present in two non-obstructive with preserved systolic function
and AF patients (#38 and #39) and one with obstruction (#16).
Myosin-binding protein C mutations were present in one patient
with end-stage systolic dysfunction (#11) and one non-obstructive
with preserved systolic function, diastolic dysfunction, and massive
LV hypertrophy in normal sinus rhythm (without restrictive physi-
ology) (#42). Troponin I mutation was present in a patient with
predominant diastolic dysfunction and restrictive physiology
(#45) in the setting of non-obstructive with preserved systolic
function; troponin T was identiﬁed in one end-stage patient (#5).
Discussion
Despite the substantial information available regarding the patho-
physiology and natural history of HCM, certain aspects of this
heterogeneous disease remain incompletely understood.
2 Although
the risks of sudden cardiac death have generally dominated the
HCM literature,
3,4,16 progressive disability and heart failure is also
an important complication of the disease.
2 In the Padua tertiary
HCM Center, 17% of patients enrolled in this study developed
advanced heart failure. These patients were predominantly women
(i.e. 54%), consistent with a prior report.
17 Furthermore, we
found heart failure symptoms progressed along three predominant
pathways, i.e. LV systolic dysfunction, outﬂow obstruction, and the
absence of obstruction with preserved systolic function.
It should be underscored that we assigned individual patients to
one of these three categories based on the predominant disease
variable, that is, that regarded clinically to be most responsible
for heart failure. Since HCM is a heterogeneous disease entity,
often with multiple pathophysiological components operating,
2 it
is an unrealistic aspiration to assemble pure clinical proﬁles
limited to single predictors of heart failure. Therefore, ultimately
the designation of a predominant pathway for those HCM patients
Figure 3 Non-obstructive hypertrophic cardiomyopathy with preserved systolic function (and atrial ﬁbrillation). A 60-year-old male patient
with a b-myosin heavy chain mutation [#39 (Table 3); #9 (Table 4)]. (A) Four-chamber view at end-diastole showing severe dilatation of both
atria [transverse dimension of left atrium (LA), 90 mm], normal-sized left ventricle (LV) and right ventricle (RV), and mild LV hypertrophy (ven-
tricular septum, VS; 18 mm) as well as preserved systolic function. (B) Heart removed at transplantation. (C) Histological section of left ven-
tricular free wall (LVFW) showing the absence of replacement ﬁbrosis. Trichrome stain ×3. (D) High-power view of area in box in (C) showing
increased interstitial ﬁbrosis. Trichrome stain ×40. (E) Thrombus within LA appendage (arrow). RA, right atrium.
Proﬁles of heart failure in HCM 2119with mixed proﬁles was necessarily based on the clinical judgement
of the investigators, taking into account the available data and per-
sonal knowledge of the individual patient.
About 30% of our patients with severe heart failure had systolic
dysfunction (ejection fraction ,50%), designated as the ‘end-stage’
phase.
14 This evolution, with or without LV chamber remodel-
ling,
14,18,19 has been reported in 3–5% of HCM cohorts.
14,18 End-
stage progression in our patients was generally slow, unpredictable,
and frequently associated with AF.
14,20 On average, 11 years
elapsed between HCM diagnosis and onset of heart failure symp-
toms, but only 4 additional years until death or heart transplan-
tation. We analysed four hearts from these end-stage patients
and found LV chamber dilatation and wall thinning due to extensive
replacement ﬁbrosis involving both ventricular septum and free
wall.
14 In such HCM patients, recurrent and silent myocardial
ischaemia may lead to extensive myocardial scarring and loss of
contractile function, associated with LV chamber remodelling.
11,14
Severe heart failure was due largely to LV outﬂow obstruction in
20% of our cases. This observation is consistent with larger cohort
studies in which obstruction proved to be a strong determinant of
progressive heart failure and death.
15 Notably, of the 11 patients in
this subgroup, 6 also had AF, a combination of abnormalities which
are particularly adverse in HCM.
20
In many cases (nearly 50%), heart failure occurred in the clinical
setting of non-obstructive disease with preserved systolic function,
eitherwithorwithoutAF,presentingaparticularlymalignantprogno-
sis. In fact, when compared with the other two progressive heart
failure subgroups, these non-obstructive patients became sympto-
matic and experienced advanced heart failure and adverse outcome
earlier. Non-obstructive patients in sinus rhythm deteriorated to
NYHA classes III–IV associated with diastolic dysfunction (with or
without restrictive LV ﬁlling patterns physiology) or AF.
21–23 Pheno-
typic expression in this latter restrictive subgroup consisted of small
ventricularcavities, markedlyenlargedatria and mild LV hypertrophy
(with restrictive LV ﬁlling pattern), or alternatively with massive LV
hypertrophy and diminutive ventricular cavities.
Noteworthy, in two-thirds of the study patients, AF contributed
to a variety of adverse clinical proﬁles,
20,24 proving be the single
Figure 4 Non-obstructive hypertrophic cardiomyopathy with preserved systolic function. Restrictive form of heart failure due to diastolic
dysfunction in sinus rhythm. A 28-year-old woman with troponin I mutation [#45 (Table 3); #12 (Table 4)]. (A) Four-chamber view in end-
diastole showing dilatation of both atria (left atrium, LA ¼ 53 mm), normal-sized ventricles, and mild ventricular septal (VS) thickening
(17 mm). (B) Pulsed Doppler waveform with evidence of restrictive ﬁlling: E/A .2; deceleration time , 150 ms. (C) long-axis left ventricular
(LV) plane with mild VS hypertrophy (17 mm); atria missing due to transplantation. (D and E) LV free wall (D) and septum (E) showing diffuse
myocardial disarray, mild interstitial ﬁbrosis, and intramural small vessel disease. Trichrome stain ×40. LVFW, left ventricular free wall; RA, right
atrium; RV, right ventricle.
P. Melacini et al. 2120most important factor in heart failure evolution overall. There have
been few pathological studies reported in patients with HCM and
AF. We identiﬁed mobile thrombi in the left atrial appendage of
ﬁve AF patients in whom the gross heart could be examined
(including three with peripheral embolization in the absence of
therapeutic anticoagulation).
25 These thrombi were unrecognized
by transthoracic echocardiography in each case. Such observations
underscore the value of transoesophageal echocardiography in
patients with HCM and AF.
Genetic screening was feasible only in a small proportion of our
cohort patients (about one-third), prohibiting deﬁnitive genotype–
phenotype correlations. However, our data do underscore that
heart failure in HCM is associated with heterogeneous genetic sub-
strates. Seventy per cent of the gene-positive patients identiﬁed
had a variety of mutations in either the b-myosin heavy chain or
myosin-binding protein C genes, the predominant disease-causing
mutant genes in any HCM population.
26 The remaining patients
had either troponin T or I mutations. Since such sarcomere
protein mutations can cause both HCM and dilated
cardiomyopathy,
27 the present ﬁndings in HCM with systolic dys-
function suggest a ﬁnal common pathway for these two primary
myocardial diseases.
In conclusion, we have distinguished three diverse pathways of
progressive heart failure in a large HCM referral cohort. Atrial
ﬁbrillation was the most common pathophysiological variable
associated with progressive heart failure. Extensive transmural
myocardial scarring inﬂuences progression to end-stage systolic
dysfunction. However, no consistent relationship was evident
between genetic substrate and heart failure proﬁle, underscoring
the broad heterogeneity of HCM from both molecular and clinical
perspectives. Recognition of the diverse pathophysiology under-
lying progressive heart failure in HCM offers a measure of clarity
to the selection of targeted management strategies, e.g. anti-
arrhythmic and other drug therapies (or radiofrequency ablation)
for AF; surgical myectomy (or, selectively, alcohol ablation) for
LV outﬂow obstruction, or timely heart transplantation for end-
stage systolic or refractory diastolic dysfunction in the absence
of LV outﬂow obstruction.
Figure 5 Non-obstructive hypertrophic cardiomyopathy with preserved systolic function. A 12-year-old girl with massive septal hypertrophy
in sinus rhythm with a myosin-binding protein C mutation [#42 (Table 3); #11 (Table 4)]. (A) Parasternal long-axis view at end-diastole, showing
marked septal hypertrophy (30 mm) and normal-sized left ventricular (LV) cavity. (B) Explanted heart, showing massive asymmetric hypertro-
phy of ventricular septum (VS), and absence of grossly visible scars. (C and D) Sections of left ventricular free wall (LVFW) (C) and VS (D)
showing myocyte hypertrophy and disarray, and increased interstitial ﬁbrosis. Trichrome stain, ×20 and ×40.
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Table 4 Pathological ﬁndings in 12 patients with hypertrophic cardiomyopathy and advanced heart failure
No. Patient # Age at death/
transplant (years)
Source Heart
weight (g)
Atrial
thrombi
Wall thickness
(mm)
LV chamber
dilatation
a
MB CAD Replacement
ﬁbrosis
b
SVD Myocyte
disarray
b
VS LVFW RV VS LVFW
End-stage
1 #4 50 Transplant 520
c n/a 17 17 7 2+ 00 3 + 3+ 01 +
2 #8 55 Autopsy 700 + 23 16 6 1++ 03 + 3++ 3+
3 #5 59 Transplant 500
c n/a 17 13 6 3++ + 3+ 1++ 1+
4 #11 63 Transplant 350
c n/a 15 13 4 2+ 00 3 + 3+ 01 +
517+143
Non-obstructive with preserved systolic function
5 #28 20 Transplant 340
c n/a 15 14 6 1+ 00 00 + 1+
6 #31 34 Autopsy 380 + 20 18 4 1++ 01 + 0 + 1+
7 #27 39 Autopsy 440 + 15 12 7 0 0 0 0 0 + 3+
8 #33 53 Autopsy 420 + 16 14 6 0 + 01 + 0 + 3+
9 #39 60 Transplant 530
c + 17 17 7 0 + 00 0 0 1 +
10 #43 9 Transplant 120
c n/a 8 8 4 0 + 00 0 0 1 +
11 #42 12 Transplant 470
c n/a 30 13 7 0 0 0 1+ 0 + 3+
12 #45 28 Transplant 370
c n/a 16 12 6 0 + 01 + 0 + 3+
384+122
CAD, (atherosclerotic) coronary artery disease; LV, left ventricle; LVFW, left ventricular free wall; MB, myocardial bridge; n/a, not available; RV, right ventricle; SVD, small vessel disease; VS, ventricular septum.
aLV chamber dilatation semi-quantitatively graded on visual inspection from 0 to 3+ (0, absent; 1+, mild, 2+, moderate; 3+, severe).
bMyocyte disarray and myocardial replacement ﬁbrosis graded on histological sections semi-quantitatively from 0 to 3+ (0, absent; 1+, mild; 2+, moderate; 3+, severe); +, present; 0, absent.
cAtria partially or totally missing.
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